Welcome to our dedicated page for Adlai Nortye Group Ltd. SEC filings (Ticker: ANL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adlai Nortye Ltd. filings document foreign private issuer reports for a clinical-stage oncology biotechnology company whose securities trade as American depositary shares. The company’s Form 6-K reports include pipeline disclosures for AN9025, AN4035, AN8025, AN4005 and AN0025; clinical and regulatory updates; unaudited financial results; corporate presentations; and material agreements.
ANL filings also record capital-structure matters, including private-placement securities purchase agreements and ADS-to-Class A ordinary share references, as well as shareholder meeting materials, proxy cards, board and committee changes, executive appointments, and the adoption of a share incentive plan.
Adlai Nortye Ltd. submitted a Form 6-K as a foreign private issuer for October 2025. The filing primarily provides materials for an upcoming extraordinary general meeting of shareholders, including a formal notice of the meeting and a proxy card for shareholders to use when voting.
Adlai Nortye Ltd. filed an S-8 registration to register securities for an employee benefit plan. The filing contains the registrant's standard undertakings to file post-effective amendments to include required prospectuses, reflect material changes after effectiveness, and remove unsold securities at the end of the offering. The exhibit list shows a legal opinion on validity of the securities from Maples and Calder (Hong Kong) LLP, auditor consents from BDO China Shu Lun Pan and Mazars USA, a powers of attorney, and a calculation of the filing fee. The form is signed by Yang Lu as Chief Executive Officer and Chairman of the Board and as Director of Adlai Nortye USA Inc.